Dr. Torsten Ryman is an expert in the area of ophthalmological research and is TFS’ Scientific Advisor in Ophthalmology.
Dr. Ryman brings 35 years of industry experience in large pharma from his previous positions at Novartis, AstraZeneca and Bayer. His clinical trial experience includes programs in various ophthalmological indications such as wet age-related macular degeneration (wAMD); cystoid macular edema (CME); retinal vein occlusion (RVO) inclusive of both central and branch retinal vein occlusion; diabetic retinopathy; and, pathological myopia. As Operative Program Leader and Scientific expert with the Ophthalmic Franchise, Novartis AG, Dr. Ryman headed the development program for Lucentis®. In this role, he was responsible for the oversight of planning and execution of the full study program that involved over 25 studies across multiple development stages, Phase II – IV and observation studies.
In addition to his extensive ophthalmology experience, Dr. Ryman has experience in the areas of cardiovascular and cerebrovascular disease, metabolic disease, CNS, infectious disease, anesthetics and urology. His professional history includes extensive collaborations between the pharmaceutical industry and CROs through his various leadership roles in both organizations.
Dr. Ryman received his doctoral degree in medical sciences from the Department of Clinical Pharmacology, University of Lund, Sweden in 2000. He received his Master of Science in Pharmacy from Uppsala University, Sweden after completing undergraduate degrees in Chemistry and Psychology.